Spinogenix Announces Launch of a Phase 2 Clinical Trial Evaluating SPG302 for the Treatment of Schizophrenia

Phase 2 trial is designed to evaluate the safety, efficacy, tolerability, and pharmacodynamics of SPG302 in adults with a primary diagnosis of schizophrenia LOS ANGELES, Calif., September 25, 2024 — Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives of patients worldwide, today announced that with the approval…

Spinogenix Announces Open Enrollment for Phase 2 Study Evaluating SPG302 for the Treatment of Alzheimer’s Disease

SPG302 is a once-a-day pill with the potential to regenerate synapses to reverse declines in cognitive function in people with Alzheimer’s disease LOS ANGELES, Calif., August 1, 2024 — Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives of patients worldwide, today announced that enrollment is now open…

Spinogenix Announces Enrollment is Open for its Phase 2 Clinical Trial of SPG601 Fragile X syndrome

U.S. FDA has granted Orphan Drug Designation to SPG601 for the Treatment of Fragile X SPG601 is a novel small molecule that works by correcting specific synaptic dysfunctions in the brain to address core symptoms of Fragile X syndrome LOS ANGELES, Calif., July 23, 2024 — Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore…

Spinogenix Announces Approval from the Australia Human Research Ethics Committee to Initiate a Phase 2 Human Clinical Trial of SPG302 for the Treatment of Alzheimer’s Disease

Phase 2 study is designed to evaluate the safety, tolerability, and pharmacodynamics of SPG302 in adult participants with mild-to-moderate Alzheimer’s disease. SPG302 is also being evaluated in a Phase 1/2 study in ALS, which has completed dosing of healthy volunteer cohorts, showing dose proportionality, tolerability, and plasma levels aligned with efficacy in animal models. LOS…

Spinogenix Announces FDA Clearance of IND Application for SPG302, a Novel Therapy for the Treatment of ALS

SPG302 is being developed as a once-a-day pill with the potential to regenerate synapses to reverse declines in cognitive and motor function in people with ALS LOS ANGELES, Calif., May 29, 2024 — Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives of patients worldwide, today announced that…

Spinogenix Announces U.S. FDA Orphan Drug Designation Granted to SPG601 for the Treatment of Fragile X syndrome

Receiving Orphan Drug Designation for SPG601 emphasizes the pressing demand for novel therapies for individuals living with Fragile X syndrome LOS ANGELES, Calif., May 20, 2024 — Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives of patients worldwide, today announced that the U.S. Food and Drug Administration…

Spinogenix Announces U.S. FDA Approval of its Investigational New DrugApplication for its Phase 2a Clinical Trial of SPG601 for Fragile X syndrome

SPG601 is a once-a-day pill that works by restoring synaptic function to address core symptoms of Fragile X syndrome LOS ANGELES, Calif., April 15, 2024 — Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives of patients worldwide, today announced that the U.S. Food and Drug Administration (FDA)…

Spinogenix Announces Second Grant Award from U.S. Department of Defense to Further Advance SPG302, the First Synaptic Regenerative Drug to Treat Amyotrophic Lateral Sclerosis (ALS)

LOS ANGELES, Calif., Sept. 26, 2023 — Spinogenix, Inc., a clinical-stage biopharmaceutical company developing novel small molecule drugs for neurodegenerative conditions, today announced that it has been awarded a new grant for nearly $1 million from the U.S. Department of Defense’s (DoD) Congressionally Directed Medical Research Programs (CDMRP). The support will allow Spinogenix to complete…

Spinogenix Awarded $3 Million NIH Grant to Support Continued Development of SPG302, the First Synaptic Regenerative Therapeutic for Alzheimer’s Disease

Treatment Could Help Restore Brain Functions Lost in Many Neurodegenerative Disorders LOS ANGELES, Calif., (September 12, 2023) – Spinogenix, Inc., a clinical-stage biopharmaceutical company developing novel small molecule drugs for neurological conditions, today announced a second grant award by the National Institute of Health (NIH). The new $3 million grant titled “Development of a Novel,…

Spinogenix Receives Approval from the Australia Human Research Ethics Committee to Initiate a Phase 1 Human Clinical Trial of SPG302, a Novel Regenerative Drug for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Treatment Could Help Restore Brain Functions Lost in Many Neurodegenerative Disorders LOS ANGELES, Calif., July 10, 2023 (GLOBE NEWSWIRE) — Spinogenix, Inc., a clinical-stage biopharmaceutical company developing novel small molecule drugs for neurological conditions, today announced that it is open to enrollment having received approval from Australia’s Human Research Ethics Committee (HREC) on June 26th…